secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001213900-24-095195
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants
-----------------------------------------------------------------------------

- Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.
- Raised $5.1M via ATM and $4.7M from warrant exercises, totaling $9.8M.
- FDA discussions advancing on tecarfarin Phase 3 LVAD trial protocol; Abbott collaboration ongoing.
- CDMO completed readiness to supply API and clinical trial materials under cGMP.
- Joined Anticoagulation Forum Corporate Council to engage 15,000 healthcare professionals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/0001213900-24-095195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/ea0220315-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-095195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer